Open AccessAnlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China
Author(s) -
Haiyong Ye,
Zhaoyi Li,
Kangning Liu,
Feng Zhang,
Changyong Zhou
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000025709
Subject(s) - medicine , hazard ratio , odds ratio , confidence interval , cochrane library , meta analysis , adverse effect , lung cancer , oncology